CPRX - Catalyst Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.525
+0.005 (+0.198%)
As of 1:06PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.520
Open2.510
Bid2.510 x 400
Ask2.520 x 400
Day's Range2.507 - 2.560
52 Week Range0.940 - 3.200
Volume78,757
Avg. Volume654,915
Market Cap213.5M
Beta1.24
PE Ratio (TTM)-12.38
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press2 months ago

    Catalyst reports 2Q loss

    On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 5 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Investopedia4 months ago

    Three Junior Biotechs Ready to Run

    Junior biotechs are attracting strong speculative interest that could offer outstanding returns for traders with well-honed risk management skills.

  • Associated Press5 months ago

    Catalyst reports 1Q loss

    On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 6 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?
    Zacks6 months ago

    What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?

    Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report first-quarter 2017 results on May 11.

  • Catalyst Pharmaceuticals Inc (CPRX): Here’s What’s Next
    Insider Monkey7 months ago

    Catalyst Pharmaceuticals Inc (CPRX): Here’s What’s Next

    After struggling throughout the latter half of 2016 with various development and regulatory pressures, Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has finally found some reprieve. Said reprieve comes in the form of some data just put out relating to the company’s lead development candidate (although not related to said candidate’s lead indication directly) and Catalyst is running […]

  • Associated Press7 months ago

    Catalyst reports 4Q loss

    On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 5 cents. For the year, the company reported that its loss widened to $18.1 million, or 22 cents per share. In the final ...

  • Investopedia7 months ago

    Catalyst Pharma Neuromuscular Drug Succeeds In Study

    Catalyst stock hit a 52-week high after its Firdapse drug reported positive study results.

  • Here’s Why Traders Are Piling Into These Five Stocks
    Insider Monkey7 months ago

    Here’s Why Traders Are Piling Into These Five Stocks

    All three major indexes are in the green today as investors look forward to today’s FOMC meeting decision. Among the stocks that are also in bull-mode are Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), Capital Bank Financial Corp (NASDAQ:CBF), Msci Inc (NYSE:MSCI), Finisar Corporation (NASDAQ:FNSR), and Whiting Petroleum Corp (NYSE:WLL). Let’s find out why traders are hitting the buy […]

  • Reuters7 months ago

    Catalyst Pharma's neuromuscular drug succeeds in study

    Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study. The drug, Firdapse, was being tested on seven patients with Musk-MG, a rare subpopulation of MG patients. There are currently no therapies for this form of MG approved by the U.S. Food and Drug Administration (FDA).

  • Harvard Bioscience, Inc. (HBIO): Are Hedge Funds Right About This Stock?
    Insider Monkey10 months ago

    Harvard Bioscience, Inc. (HBIO): Are Hedge Funds Right About This Stock?

    At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Third Point because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]

  • Alexion (ALXN) Offers Long-Term Phase III Data on Kanuma
    Zacks11 months ago

    Alexion (ALXN) Offers Long-Term Phase III Data on Kanuma

    Alexion Pharmaceuticals, Inc. (ALXN) revealed new long-term data from an ongoing, open-label extension of the pivotal phase III ARISE study on Kanuma

  • Zacks11 months ago

    Catalyst Pharma (CPRX) Q3 Earnings: Will Stock Surprise?

    Catalyst Pharmaceuticals, Inc. (CPRX) is scheduled to report third-quarter 2016 results on Nov 9, after market close.

  • Investopedia11 months ago

    Catalyst Reaches Agreement with FDA (CPRX)

    After initial NDA submission for Firdapse was rejected by the FDA earlier this year, the new agreement suggests approval may be forthcoming.

  • Catalyst Pharmaceuticals Inc (CPRX) Isn’t Out Of The Woods With Firdapse Just Yet
    Insider Monkey11 months ago

    Catalyst Pharmaceuticals Inc (CPRX) Isn’t Out Of The Woods With Firdapse Just Yet

    Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) just announced that it is carrying forward with a special protocol assessment (SPA) for its lead asset, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), in the second of two planned phase 3 investigations that will underpin a new drug application for the treatment. The company is up on the […]